99 related articles for article (PubMed ID: 16616492)
1. A practical synthesis of the major 3-hydroxy-2-pyrrolidinone metabolite of a potent CDK2/cyclin A inhibitor.
Nesi M; Borghi D; Brasca MG; Fiorentini F; Pevarello P
Bioorg Med Chem Lett; 2006 Jun; 16(12):3205-8. PubMed ID: 16616492
[TBL] [Abstract][Full Text] [Related]
2. Triazolo[1,5-a]pyrimidines as novel CDK2 inhibitors: protein structure-guided design and SAR.
Richardson CM; Williamson DS; Parratt MJ; Borgognoni J; Cansfield AD; Dokurno P; Francis GL; Howes R; Moore JD; Murray JB; Robertson A; Surgenor AE; Torrance CJ
Bioorg Med Chem Lett; 2006 Mar; 16(5):1353-7. PubMed ID: 16325401
[TBL] [Abstract][Full Text] [Related]
3. Modulating the interaction between CDK2 and cyclin A with a quinoline-based inhibitor.
Deng Y; Shipps GW; Zhao L; Siddiqui MA; Popovici-Muller J; Curran PJ; Duca JS; Hruza AW; Fischmann TO; Madison VS; Zhang R; McNemar CW; Mayhood TW; Syto R; Annis A; Kirschmeier P; Lees EM; Parry DA; Windsor WT
Bioorg Med Chem Lett; 2014 Jan; 24(1):199-203. PubMed ID: 24332088
[TBL] [Abstract][Full Text] [Related]
4. Fascaplysin-inspired diindolyls as selective inhibitors of CDK4/cyclin D1.
Aubry C; Wilson AJ; Emmerson D; Murphy E; Chan YY; Dickens MP; García MD; Jenkins PR; Mahale S; Chaudhuri B
Bioorg Med Chem; 2009 Aug; 17(16):6073-84. PubMed ID: 19632122
[TBL] [Abstract][Full Text] [Related]
5. Truncation and optimisation of peptide inhibitors of cyclin-dependent kinase 2-cyclin a through structure-guided design.
Kontopidis G; Andrews MJ; McInnes C; Plater A; Innes L; Renachowski S; Cowan A; Fischer PM
ChemMedChem; 2009 Jul; 4(7):1120-8. PubMed ID: 19472269
[TBL] [Abstract][Full Text] [Related]
6. Benzothiophene inhibitors of MK2. Part 1: structure-activity relationships, assessments of selectivity and cellular potency.
Anderson DR; Meyers MJ; Kurumbail RG; Caspers N; Poda GI; Long SA; Pierce BS; Mahoney MW; Mourey RJ
Bioorg Med Chem Lett; 2009 Aug; 19(16):4878-81. PubMed ID: 19616945
[TBL] [Abstract][Full Text] [Related]
7. A convenient synthesis and molecular modeling study of novel purine and pyrimidine derivatives as CDK2/cyclin A3 inhibitors.
Elgazwy AS; Ismail NS; Elzahabi HS
Bioorg Med Chem; 2010 Nov; 18(21):7639-50. PubMed ID: 20851615
[TBL] [Abstract][Full Text] [Related]
8. 3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 2. Lead optimization.
Pevarello P; Brasca MG; Orsini P; Traquandi G; Longo A; Nesi M; Orzi F; Piutti C; Sansonna P; Varasi M; Cameron A; Vulpetti A; Roletto F; Alzani R; Ciomei M; Albanese C; Pastori W; Marsiglio A; Pesenti E; Fiorentini F; Bischoff JR; Mercurio C
J Med Chem; 2005 Apr; 48(8):2944-56. PubMed ID: 15828833
[TBL] [Abstract][Full Text] [Related]
9. Pyrazolobenzodiazepines: part I. Synthesis and SAR of a potent class of kinase inhibitors.
Liu JJ; Daniewski I; Ding Q; Higgins B; Ju G; Kolinsky K; Konzelmann F; Lukacs C; Pizzolato G; Rossman P; Swain A; Thakkar K; Wei CC; Miklowski D; Yang H; Yin X; Wovkulich PM
Bioorg Med Chem Lett; 2010 Oct; 20(20):5984-7. PubMed ID: 20832307
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and biological study of novel pyrido[2,3-d]pyrimidine as anti-proliferative CDK2 inhibitors.
Ibrahim DA; Ismail NS
Eur J Med Chem; 2011 Dec; 46(12):5825-32. PubMed ID: 22000924
[TBL] [Abstract][Full Text] [Related]
11. Searching for cyclin-dependent kinase inhibitors using a new variant of the cope elimination.
Griffin RJ; Henderson A; Curtin NJ; Echalier A; Endicott JA; Hardcastle IR; Newell DR; Noble ME; Wang LZ; Golding BT
J Am Chem Soc; 2006 May; 128(18):6012-3. PubMed ID: 16669651
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of aminopyrazole analogs and their evaluation as CDK inhibitors for cancer therapy.
Rana S; Sonawane YA; Taylor MA; Kizhake S; Zahid M; Natarajan A
Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3736-3740. PubMed ID: 30343954
[TBL] [Abstract][Full Text] [Related]
13. Discovery and evaluation of dual CDK1 and CDK2 inhibitors.
Payton M; Chung G; Yakowec P; Wong A; Powers D; Xiong L; Zhang N; Leal J; Bush TL; Santora V; Askew B; Tasker A; Radinsky R; Kendall R; Coats S
Cancer Res; 2006 Apr; 66(8):4299-308. PubMed ID: 16618755
[TBL] [Abstract][Full Text] [Related]
14. 3-Amino-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: a new class of CDK2 inhibitors.
Pevarello P; Fancelli D; Vulpetti A; Amici R; Villa M; Pittalà V; Vianello P; Cameron A; Ciomei M; Mercurio C; Bischoff JR; Roletto F; Varasi M; Brasca MG
Bioorg Med Chem Lett; 2006 Feb; 16(4):1084-90. PubMed ID: 16290148
[TBL] [Abstract][Full Text] [Related]
15. Discovery of a potent CDK2 inhibitor with a novel binding mode, using virtual screening and initial, structure-guided lead scoping.
Richardson CM; Nunns CL; Williamson DS; Parratt MJ; Dokurno P; Howes R; Borgognoni J; Drysdale MJ; Finch H; Hubbard RE; Jackson PS; Kierstan P; Lentzen G; Moore JD; Murray JB; Simmonite H; Surgenor AE; Torrance CJ
Bioorg Med Chem Lett; 2007 Jul; 17(14):3880-5. PubMed ID: 17570665
[TBL] [Abstract][Full Text] [Related]
16. Virtual screening studies to design potent CDK2-cyclin A inhibitors.
Vadivelan S; Sinha BN; Irudayam SJ; Jagarlapudi SA
J Chem Inf Model; 2007; 47(4):1526-35. PubMed ID: 17523616
[TBL] [Abstract][Full Text] [Related]
17. Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitors.
Dwyer MP; Paruch K; Alvarez C; Doll RJ; Keertikar K; Duca J; Fischmann TO; Hruza A; Madison V; Lees E; Parry D; Seghezzi W; Sgambellone N; Shanahan F; Wiswell D; Guzi TJ
Bioorg Med Chem Lett; 2007 Nov; 17(22):6216-9. PubMed ID: 17904366
[TBL] [Abstract][Full Text] [Related]
18. Benzamide capped peptidomimetics as non-ATP competitive inhibitors of CDK2 using the REPLACE strategy.
Premnath PN; Craig SN; Liu S; McInnes C
Bioorg Med Chem Lett; 2016 Aug; 26(15):3754-60. PubMed ID: 27297568
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and structure-activity relationships of novel indirubin derivatives as potent anti-proliferative agents with CDK2 inhibitory activities.
Moon MJ; Lee SK; Lee JW; Song WK; Kim SW; Kim JI; Cho C; Choi SJ; Kim YC
Bioorg Med Chem; 2006 Jan; 14(1):237-46. PubMed ID: 16182537
[TBL] [Abstract][Full Text] [Related]
20. Benzothiophene inhibitors of MK2. Part 2: improvements in kinase selectivity and cell potency.
Anderson DR; Meyers MJ; Kurumbail RG; Caspers N; Poda GI; Long SA; Pierce BS; Mahoney MW; Mourey RJ; Parikh MD
Bioorg Med Chem Lett; 2009 Aug; 19(16):4882-4. PubMed ID: 19616942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
